JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri as a $7B product by 2033 in its lead indication alone and believes Insmed has several share catalysts over the next 12 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed initiated with an Outperform at William Blair
- Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks
- Insmed price target raised to $145 from $121 at Stifel
- Insmed price target raised to $139 from $126 at Truist